Zhonghong Pulin Medical Products 中红医疗
3 significant filings since 30 May 2026: 1 on buyback, 1 on guarantee or financial assistance and 1 on earnings pre-announcement. The latest, on 23 Sep 2026: 关于以集中竞价方式出售已回购股份的预披露公告. On 29 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 2,338.00% to 3,557.00% from the same period a year earlier.
自 30 May 2026 起有 3 份重大公告：buyback 1 份、guarantee or financial assistance 1 份、earnings pre-announcement 1 份。最新一份（23 Sep 2026）：关于以集中竞价方式出售已回购股份的预披露公告。29 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 2,338.00% 至 3,557.00%。
Price History 价格走势
1 session 个交易日, Thu 24 Sep 2026 · Live one-minute prices · High 最高 ¥18.10 · Low 最低 ¥17.56 · −4.14% on the previous close of ¥18.37| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥76亿 | ¥47亿 | 46th highest of 140 · 140 家中第 46 高 | |
| Trailing P/E 市盈率 | 186.4x | 40.4x | 12th highest of 101 · 101 家中第 12 高 | |
| P/B 市净率 | 1.4x | 2.4x | 26th lowest of 140 · 140 家中第 26 低 | |
| Revenue Growth 营收增速 | 19.5% | 4.0% | 27th highest of 140 · 140 家中第 27 高 | |
| Profit Growth 净利增速 | 2,662.4% | -2.6% | Highest of 140 · 140 家中第 1 高 | |
| Gross Margin 毛利率 | 24.0% | 55.2% | 14th lowest of 140 · 140 家中第 14 低 | |
| Net Margin 净利率 | 10.7% | 10.7% | 70th highest of 140 · 140 家中第 70 高 | |
| Return on Equity 净资产收益率 | 3.0% | 2.4% | 64th highest of 140 · 140 家中第 64 高 | |
| Debt to Assets 资产负债率 | 29.5% | 19.2% | 43rd highest of 140 · 140 家中第 43 高 | |
| Grade Score 评级得分 | 57 | 52 | 46th highest of 140 · 140 家中第 46 高 |
Statement figures are for the period to 30 Jun 2026, filed by 140 of 140 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，140 家同业中 140 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Shenzhen Mindray Bio-Medical Electronics 迈瑞医疗 | ¥1,864亿 | 23.7x | 4.6x | 6.0% | 28.4% | 12.0% | C |
| Shanghai United Imaging Healthcare 联影医疗 | ¥844亿 | 47.7x | 3.8x | 17.2% | 12.6% | 4.1% | D |
| Shenzhen New Industries Biomedical 新产业 | ¥375亿 | 21.8x | 4.2x | 10.8% | 35.9% | 9.3% | B |
| APT Medical 惠泰医疗 | ¥334亿 | 35.8x | 10.8x | 25.7% | 34.6% | 16.0% | B |
| Wantai Biological 万泰生物 | ¥334亿 | — | 2.8x | 24.3% | -12.6% | -1.1% | D |
| Intco Medical Technology 英科医疗 | ¥322亿 | 28.3x | 1.7x | 40.6% | 13.1% | 4.5% | C |
| MGI Tech 华大智造 | ¥312亿 | — | 4.4x | 18.9% | -11.6% | -2.2% | D |
| Andon Health 九安医疗 | ¥288亿 | 6.5x | 1.2x | -30.6% | 578.7% | 13.7% | C |
| IRAY Group 奕瑞科技 | ¥279亿 | 38.7x | 3.6x | 56.7% | 25.0% | 6.4% | C |
| Jiangsu Yuyue Medical Equipment & Supply 鱼跃医疗 | ¥262亿 | 23.4x | 2.0x | -1.9% | 18.6% | 6.2% | C |
| Weigao Blood Purification 威高血净 | ¥216亿 | 44.0x | 1.8x | -0.4% | 13.1% | 3.2% | D |
| Lepu Medical Technology 乐普医疗 | ¥210亿 | 27.3x | 1.3x | -4.6% | 14.2% | 3.0% | D |
| Zhende Medical 振德医疗 | ¥207亿 | 74.8x | 3.6x | 5.9% | 6.8% | 2.5% | D |
| Autobio 安图生物 | ¥192亿 | 19.3x | 2.2x | -0.1% | 24.4% | 5.5% | C |
| Zhonghong Pulin Medical Products 中红医疗 | ¥76亿 | 186.4x | 1.4x | 19.5% | 10.7% | 3.0% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。